3. Immune-mediated condition.
Tumor-like swelling of involved organs.
A lymphoplasmacytic infiltrate enriched in
IgG4-positive plasma cells.
A variable degree of fibrosis.
Elevated serum concentrations of IgG4
Responsiveness to glucocorticoids.
6. ↑Middle-aged and older men.
Sialadenitis & ophthalmic disease :
Males=females.
Disease extent and severity are similar in
males & females.
UNDERRECOGNITION
7.
8. IgG4: The least common (3% to 6%) of the 4
subclasses of IgG.
IgG4 may have a role in tolerance to
allergens and in responses to certain
infectious agents.
IgG4 antibodies in this disease are not
pathogenic, but rather represent a down-
regulatory response to another primary
process(es).
Autoimmune / allergic .
9.
10. Conclusions: An autoimmune mechanism against CA-II
(carbonic anhydrase II )or LF (lactoferrin), and Th1-type
immune response, may be involved in AIP.
11. 2010
no antigens/ nor specific autoantibodies
↑Th2 cytokines, IgE, IgG4,
↑ allergic rhinitis,↑bronchial asthma
? Pathogenesis/? epiphenomenon
12.
13. Asymptomatic/ Mass effect
< 2 cm, non tender, rubbery
Biopsies are problematic
storiform fibrosis↓
IgG4+ plasma cells: not specific
14. Type I – Multicentric Castleman disease-like
Type II – Follicular hyperplasia
Type III – Interfollicular expansion
Type IV – Progressive transformation of germinal
center-like
Type V – Nodal inflammatory pseudotumor-like
36. >135 mg/dL
Not specific:
Multicentric Castleman’s disease
Allergic disorders
Eosinophilic granulomatosis with polyangiitis
(Churg-Strauss)
Sarcoidosis
37. Better
Not widely available
Assess response to treatment and relapse.
38. Figure 5 Diagnostic algorithm for comprehensive diagnostic criteria for
IgG4-related disease combined with organ-specific criteria
Yamamoto, M. et al. (2013) Mechanisms and assessment of IgG4-related disease:
lessons for the rheumatologist
Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2013.183
42. The optimal treatment has not been established.
All patients with active IgG4-RD require treatment.
Glucocorticoids are the first-line agent for induction.
Certain patients benefit from maintenance therapy.
Retreatment with glucocorticoids in relapse.
Some but not all patients require the combination of glucocorticoi
and a steroid-sparing immunosuppressive agent from the start of
treatment
43. 40 mg prednisolone→ taper (2 months)
Rituximab: (1 gram IV every 15 days for
a total of two doses)
Azathioprine: (2 mg/kg/day)
MMF:(up to 2.5 g/day)
44.
45. Not well-defined.
Improvement without treatment.
Morbidity and mortality:
• cirrhosis
• portal hypertension
• retroperitoneal fibrosis
• aortic aneurysmal dissection
• biliary obstruction
• diabetes mellitus
Subacute constitutional symptoms marked by
fatigue and weight loss
46. Debate ???
Malignancy is associated with subsequent developm
of IgG4-RD.